(Date:11/23/2009)...-FirstCall/-- ,, DearIsisSupportersandSharehold...ntinuingsupportofIsis.Webelieveweareatoneofthemost...thebeginningofcreatingauniquecompanywithanoveldrug...issueshauntingthepharmaceuticalindustry. ,, Our...shipdrug,mipomersen.Mipomersencontinuestoperformwe...
(Date:11/23/2009)...ylCompanies,thenation,sleadingproviderofoutsourced...edrecognitionasoneofthetopoutsourcingfirmsinhealth...magazine.Berylwasrankedamongthepublication,stop20o...hichenabledittoclimbfromtwelfthplacein2007totenthp...veproducts,suchasitsnewestlaunchofpost-dischargese...
(Date:11/23/2009)...rstCall/--ArcadiaResources,Inc.(NYSEAmex: KAD ),al...esundertheArcadiaHealthCare(SM)()brand,announcedto...haresofitscommonstockandwarrantstopurchasecommonst...nalinvestors,representinggrossproceedstoArcadiaofa...arateSubscriptionAgreementswiththeinvestors,Arcadi...
(Date:11/23/2009)...ascular Services, a division of Baptist Medical Ce...ddition of Aquapheresis Therapy using the Aquadex ...t of patients with fluid overload – helping ... Jackson, Miss. (Vocus) November 2...om fluid overload, time is of the essence. Excess ...
(Date:11/23/2009)...al,sDirectNutritionals,LLC,worldwidedistributorofD...siteCookieDiet.com( www.CookieDiet.com ),todayanno...pularhunger-satisfyingcookiesareavailableonSamsclu...,Sam,sClub. ,, "We,reproudtowelcomeSamsclub.com...l,sCookieDietproducts,andtheonlymembershipdiscount...
Breaking Medicine News(10 mins):Health News:The Beryl Companies Named One of the 'Top 10 Outsourcing Firms' in Healthcare 2Health News:Arcadia Resources Announces Closing of $11.1 Million Financing 2Health News:Baptist Cardiovascular Services Introduces New Technology for Congestive Heart Failure Treatment 2Health News:Baptist Cardiovascular Services Introduces New Technology for Congestive Heart Failure Treatment 3Health News:Dr. Siegal's COOKIE DIET(R) Cookies Available at Samsclub.com 2(Date:11/20/2009)...ISBURG, Pa., Nov. 20 Th...H1N1 flu shots to members of priority groups that ... A total of 18 clinics are being held statewide on... to 8 p.m. Hours on Saturday, Nov. 21, will be 8 a... operate from 2 p.m. to 8 p.m. ,, Individuals ...
(Date:11/20/2009)...EW YORK, Nov. 20 ,, Reportlink... is available in its catalogue. ,, India Medic... ,, http://www.reportlinker.com/p0164658/Ind...-to-2015.html#utm_source=prnewswire&utm_medium...on ,, India Medical Equipment Market Analysis ...
(Date:11/20/2009)...CK, Mass. and LONDON, Nov. 20 /PRNewswire-FirstCal... today announced that it has received 510(k) clear...DA) and CE Mark approval to market its WallFlex...nt of malignant esophageal strictures (obstruction... non-resectable esophageal cancer. ,, (Photo: ...
Breaking Medicine Technology:Pennsylvania Department of Health Begins Statewide H1N1 Vaccination Clinics Targeting Priority Populations; Some Appointments Still Available 2Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 2Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 3Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 4Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 5Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 6Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 7Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 8Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 9Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 10Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 11Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 12Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 13Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 2Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 3Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 4Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update 13364 1Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update 13364 2Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update 13364 3Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update 13364 4Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update 13364 5Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update 13364 6Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update 13364 7Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update 13364 8Keryx Biopharmaceuticals Inc to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday August 6 2009 at 8 3A30am EDT 13361 1Keryx Biopharmaceuticals Inc to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday August 6 2009 at 8 3A30am EDT 13361 2ARUP Laboratories Applauds FDAs Decision on the Value of KRAS Mutation Testing in Colorectal Cancer 4822 1ARUP Laboratories Applauds FDAs Decision on the Value of KRAS Mutation Testing in Colorectal Cancer 4822 2ARUP Laboratories Applauds FDAs Decision on the Value of KRAS Mutation Testing in Colorectal Cancer 4822 3... SyntheMed, Inc. (OTC,Bulletin Board: SYMD), a bi...commercialization of anti-adhesion, drug delivery ...day that REPEL-CV(R), the company,s,bioresorbable ...ns,following cardiac surgery, has received Health ...undergo open heart surgery. REPEL-CV will be,marke...
..., July 14 MAP,Pharmaceuticals, Inc. (Nasdaq: MAP...linical program to evaluate MAP0004 as a potential...ed and self-administered at home using MAP,Pharmac...pany,s prior Phase,2 efficacy study, MAP0004 provi...ef sustained through at least 24 hours. The study ...
Other Medicine Technology:SyntheMed Receives Canadian Approval for REPEL-CV(R) 2MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine 2MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine 3MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine 4... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
Medicine Products: